NYSE:WST - West Pharmaceutical Services Stock Price, News & Analysis

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services announced a quarterly dividend on Thursday, July 25th. Shareholders of record on Wednesday, October 23rd will be paid a dividend of $0.15 per share on Wednesday, November 6th. This represents a $0.60 annualized dividend and a yield of 0.42%. The ex-dividend date is Tuesday, October 22nd. View West Pharmaceutical Services' Dividend History.

West Pharmaceutical Services declared that its board has initiated a stock buyback plan on Thursday, February 15th 2018, which permits the company to repurchase 800,000 shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board believes its stock is undervalued.

West Pharmaceutical Services Inc. (NYSE:WST) posted its earnings results on Thursday, July, 25th. The medical instruments supplier reported $0.89 EPS for the quarter, topping the consensus estimate of $0.72 by $0.17. The medical instruments supplier earned $469.70 million during the quarter, compared to the consensus estimate of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.70 EPS. View West Pharmaceutical Services' Earnings History.

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for West Pharmaceutical Services.

West Pharmaceutical Services updated its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus estimate of $2.89. The company issued revenue guidance of $1.810-1.825 billion, compared to the consensus revenue estimate of $1.81 billion.

3 brokers have issued 1-year target prices for West Pharmaceutical Services' shares. Their predictions range from $112.16 to $122.00. On average, they anticipate West Pharmaceutical Services' share price to reach $117.08 in the next year. This suggests that the stock has a possible downside of 18.8%. View Analyst Price Targets for West Pharmaceutical Services.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for West Pharmaceutical Services.

News articles about WST stock have been trending somewhat positive on Sunday, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. West Pharmaceutical Services earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for West Pharmaceutical Services.

West Pharmaceutical Services saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 600,600 shares, an increase of 24.6% from the July 15th total of 481,900 shares. Based on an average daily volume of 292,900 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.8% of the company's stock are sold short. View West Pharmaceutical Services' Current Options Chain.

Some companies that are related to West Pharmaceutical Services include Biogen (BIIB), Humana (HUM), Siemens Healthineers (SHL), Regeneron Pharmaceuticals (REGN), ESSILOR INTL S/S (ESLOY), Actelion (ALIOF), Zimmer Biomet (ZBH), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), RESMED/IDR UNRESTR (RMD), FRESENIUS SE &/S (FSNUY), McKesson (MCK), Takeda Pharmaceutical (TAK), LONZA GRP AG/ADR (LZAGY) and COLOPLAST A/S/ADR (CLPBY).

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include Nike (NKE), NVIDIA (NVDA), Medtronic (MDT), Square (SQ), Stanley Black & Decker (SWK), Veeva Systems (VEEV), CVS Health (CVS), Honeywell International (HON), Johnson & Johnson (JNJ) and Walmart (WMT).

West Pharmaceutical Services' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (12.07%), Vanguard Group Inc. (9.93%), BlackRock Inc. (9.78%), BlackRock Inc. (9.78%), Bamco Inc. NY (2.16%) and JPMorgan Chase & Co. (2.10%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Renaissance Technologies LLC, First Trust Advisors LP, Schroder Investment Management Group, Janus Henderson Group PLC, Janus Henderson Group PLC, Royal Bank of Canada and Eagle Asset Management Inc.. View Insider Buying and Selling for West Pharmaceutical Services.

WST stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Invesco Ltd., WCM Investment Management LLC, AMI Asset Management Corp, Price T Rowe Associates Inc. MD, Amundi Pioneer Asset Management Inc., AQR Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for West Pharmaceutical Services.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WST stock can currently be purchased for approximately $144.20.

West Pharmaceutical Services has a market capitalization of $10.63 billion and generates $1.72 billion in revenue each year. The medical instruments supplier earns $206.90 million in net income (profit) each year or $2.81 on an earnings per share basis. West Pharmaceutical Services employs 7,700 workers across the globe.View Additional Information About West Pharmaceutical Services.

The official website for West Pharmaceutical Services is http://www.westpharma.com/.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]